florencegenet

Uppsala, Sweden – 13 May 2026 PeptiSystems, a life science company pioneering advanced manufacturing solutions for peptide and oligonucleotide drugs, today announced that the United States Patent and Trademark Office (USPTO) has granted a patent for its flow-through peptide manufacturing technology. The patent protects core elements of the technology, strengthening the company’s position in peptide manufacturing. Patent protection in the United States strengthens PeptiSystems’ intellectual...

30th of April, 2026 - Uppsala, Sweden PeptiSystems, a life science company pioneering advanced manufacturing solutions for peptide and oligonucleotide drugs, has appointed Ole J. Dahlberg to its Board of Directors. The appointment reflects the company’s focus on scaling commercial operations and expanding its global presence. ​ PeptiSystems develops and commercializes flow-through synthesis instruments for peptide and oligonucleotide therapeutics. The instruments are used by pharmaceutical...

13th of November, 2025 - Uppsala, Sweden PeptiSystems, a life science company developing advanced manufacturing solutions for peptide and oligonucleotide-based therapeutics, has announced a significant growth investment from Rubicon Healthcare Partners. The partnership will enable PeptiSystems to accelerate its global expansion and deliver scalable, next-generation manufacturing solutions to a rapidly growing biopharma market. Rubicon Healthcare Partners is a growth-oriented investment firm...